Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160

Tetsu Yano, Sinisa Radulovic, Yutaka Osuga, Koji Kugu, Hiroyuki Yoshikawa, Yuji Taketani, Andrew V. Schally

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

In this study, we investigated the effects of somatostatin analog RC-160 on the growth of the OV-1063 human epithelial ovarian cancer cell line in vitro. RC-160 inhibited cell proliferation, as measured by cell number, and [3H]thymidine incorporation into DNA at 10-9-10-5 M. In OV-1063 cells, 125I-labeled RC-160 was bound to one class of specific, saturable binding sites with high affinity (K(d) = 0.2 ± 0.03 nM) and low capacity (5,500 binding sites per cell).125I-labeled RC-160 could be displaced by unlabeled RC-160. Ligand binding was dependent on time and temperature. Receptor internalization assay showed that the ligand-receptor complex was internalized at 37°, which indicates the presence of biologically active somatostatin receptors on OV-1063 cells. These results suggest that somatostatin analog RC-160 can suppress the growth of OV-1063 human epithelial ovarian cancer cells by a direct action and that the inhibitory effect of somatostatin analog is mediated through the high-affinity somatostatin receptors. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
JournalOncology
Volume59
Issue numberSUPPL. 1
DOIs
StatePublished - 2000

Keywords

  • Ovarian cancer
  • Somatostatin
  • Somatostatin analog
  • Somatostatin receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160'. Together they form a unique fingerprint.

  • Cite this

    Yano, T., Radulovic, S., Osuga, Y., Kugu, K., Yoshikawa, H., Taketani, Y., & Schally, A. V. (2000). Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160. Oncology, 59(SUPPL. 1), 45-49. https://doi.org/10.1159/000055287